The selective inhibitory effect of a synthetic tanshinone derivative on prostate cancer cells

Prostate

Volumn 72, Issue 7, 2012, Pages 803-816

  Xu, Defeng ^a,b   Lin, Tzu Hua ^a   Zhang, Caixia ^c   Tsai, Yu Chieh ^d   Li, Shaoshun ^b   Zhang, Jing ^b   Yin, Min ^b   Yeh, Shuyuan ^a   Chang, Chawnshang ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

androgen receptor; anti androgen; Danshen; prostate cancer; tanshinone

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; CRYPTOTANSHINONE; ESTROGEN RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR; LUCIFERASE; MESSENGER RNA; PROGESTERONE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PTS 33; TRANSMEMBRANE PROSTATE ANDROGEN INDUCED PROTEIN A1; TRANSMEMBRANE PROTEASE SERINE 2; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; ENZYME ASSAY; GENE REPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TRANSACTIVATION; TUMOR GROWTH; WESTERN BLOTTING;

ADENOCARCINOMA; CELL LINE, TUMOR; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; PHENANTHRENES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, GLUCOCORTICOID; RECEPTORS, PROGESTERONE; SERINE ENDOPEPTIDASES;

EID: 84860335030     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21474     Document Type: Review

References (49)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, Slaga TJ,. 4-Hydroxy-3-methoxybenzoic acid methyl ester: A curcumin derivative targets Akt/NFκB cell survival signaling pathway: Potential for prostate cancer management. Neoplasia 2003; 5 (3): 255-266. (Pubitemid 36754055)
3. Huggins C, Hodges CV,. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-297.
4. Molina A, Belldegrun A,. Novel therapeutic strategies for castration resistant prostate cancer: Inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011; 185 (3): 787-794.
5. Fanning KD, Lloyd KB,. Current pharmacological treatment options for prostate cancer. Pharmacy and Therapeutics 2002; 27 (4): 500-505. (Pubitemid 36342396)
6. Suzuki H, Hinotsu S, Akaza H, Fuji Y, Kawakami S, Kihara K, Akakura K, Suzuki M, Kitamura T, Homma Y, Mizokami A,. Hormonal therapy for prostate cancer: Current topics and future perspectives. Int J Urol 2010; 17 (4): 302-313.
7. Terada N, Shimizu Y, Yoshida T, Maeno A, Kamba T, Inoue T, Nakamura E, Kamoto T, Ogawa O,. Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft. Prostate 2010; 70: 252-261.
8. Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT,. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer 2006; 13 (3): 653-666. (Pubitemid 44763250)
9. Harris WP, Mostaghel EA, Nelson PS, Montgomery B,. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6 (2): 76-85.
10. Koochekpour S,. Androgen receptor signaling and mutations in prostate cancer. Asian J Androl 2010; 12 (5): 639-657.
11. Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, Merry DE, Sobue G, Chen LM, Chang SS, Chang C,. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007; 13 (3): 348-353. (Pubitemid 46376683)
12. Cowan MM,. Plant products as antimicrobial agents. Clin Microbiol Rev 1999; 12 (4): 564-582. (Pubitemid 29484747)
13. Rout AP, Choudary KA, Das L, Jain A,. Plants in traditional medicinal system-Future source on new drugs. J Pharm Pharm Sci 2009; 1 (1): 1-23.
14. Xu DS,. Dan Shen (Radix Salviae Miltorrhizae): Biology and application. Beijing: Beijing Science Press; 1990.
15. Wang XH, Morris-Natschke SL, Lee KH,. New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 2007; 27: 133-148. (Pubitemid 44975189)
16. Hur JM, Shim JS, Jung HJ, Kwon HJ,. Cryptotanshinone but not tanshinone IIA inhibits angiogenesis in vitro. Exp Mol Med 2005; 37 (2): 133-137. (Pubitemid 40676923)
17. Park EJ, Zhao YZ, Kim YC, Sohn DH,. Cryptotanshinone, can protect against liver toxicity in vivo and in vitro due to its antioxidant effects. Food Chem Toxicol 2009; 47 (1): 2742-2748.
18. Kang BY, Chung SW, Kim SH, Ryu SY, Kim TS,. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 2000; 49 (3): 355-361.
19. Lee WY, Cheung CC, Liu KW, Fung KP, Wong J, Lai PB, Yeung JH,. Cytotoxic effects of tanshinones from salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J Nat Prod 2010; 73 (5): 854-859.
20. Shin DS, Kim HN, Shin KD, Yoon YJ, Kim SJ, Han DC, Kwon BM,. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res 2009; 69 (1): 193-202.
21. LI XH, Yang XM, Wu XK,. Effects of cryptotanshinone in lowering androgens synthesis for the prenatally androgenized male rats. Chin J Integr Tradit West Med 2008; 28 (11): 1001-1004.
22. Vilsmeier A, Haack A,. Ãber die einwirkung von halogenphosphor auf alkyl-formanilide. Eine neue methode zur darstellung sekundärer und tertiärer p-alkylamino-benzaldehyde. Ber 1927; 60: 119.
23. Meth-Cohn O, Stanforth SP,. Vilsmeier-Haack reaction. Comp Org Syn 1991; 2: 777-794.
24. Dawadi PBS, Lugtenburg J,. Efficient preparation of [2-13C]- and [3-13C]-3-cyano-4-methyl-3-pyrrolin-2-one. Eur J Org Chem 2007; 1294-1300.
25. Hekmat S, Salehi P,. Novel, Efficient, and Green Procedure for the Knoevenagel Condensation Catalyzed by Diammonium Hydrogen Phosphate in Water. Synth Commun 2006; 36: 2549-2557. (Pubitemid 44352785)
26. Jones G,. In organic reactions. Knoevenagel React 1967; 15: 204.
27. Yeh S, Lin HK, Kang HY, Thin T, Lin M, Chang C,. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci 1999; 96: 5458-5463. (Pubitemid 29234639)
28. Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, Kang HY, Chang C,. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci 2000; 97: 11256-11261.
29. Chen M, Ni J, Zhang Y, Muyan M, Yeh S,. ERAP75 functions as a coactivator to enhance estrogen receptor α transactivation in prostate stromal cells. Prostate 2008; 68: 1273-1282.
30. Chen M, Ni J, Chang HC, Lin CY, Muyan M, Yeh S,. CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells. Carcinogenesis 2009; 30: 841-850.
31. Ni J, Pang ST, Yeh S,. Differential retention of α-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells. Prostate 2007; 67: 463-471. (Pubitemid 46536940)
32. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ,. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62 (22): 6606-6614. (Pubitemid 35364127)
33. Sisecioglu M, Gulcin I, Cankaya M, Atasever A, Ozdemir H,. The effects of norepinephrine on lactoperoxidase enzyme (LPO). Sci Res Essays 2010; 5 (11): 1351-1356.
34. Hsu CL, Chen YL, Ting HJ, Lin WJ, Yang Z, Zhang Y, Wang L, Wu CT, Chang HC, Yeh S, Pimplikar SW, Chang C,. Androgen receptor (AR) NH2- and COOH-terminal interactions result in the differential influences on the AR-mediated transactivation and cell growth. Mol Endocrinol 2005; 19 (2): 350-361. (Pubitemid 40223460)
35. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson WM,. Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 1999; 274: 37219-37225.
36. Yeh S, Chang C,. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci 1996; 93 (11): 5517-5521.
37. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ,. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68 (13): 5469-5477.
38. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69 (1): 16-22.
39. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y,. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69 (6): 2305-2313.
40. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL,. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci 2010; 107 (39): 16759-16765.
41. Yeh S, Miyamoto H, Shima H, Chang C,. From estrogen to androgen receptor: A new pathway for sex hormones in prostate. Proc Natl Acad Sci 1998; 95: 5527-5532. (Pubitemid 28224128)
42. Miyamoto H, Yeh S, Lardy H, Messing E, Chang C,. Δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci 1998; 95: 11083-11088. (Pubitemid 28450085)
43. Miyamoto H, Messing EM, Chang C,. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004; 9999: 1-22.
44. Mosihuzzaman M, Choudhary MI,. Protocols on safety, efficacy, standardization, and documentation of herbal medicine. Pure Appl Chem 2008; 80 (10): 2195-2230.
45. Compagno D, Merle C, Morin A, Gilbert C, Mathieu JR, Bozec A, Mauduit C, Benahmed M, Cabon F,. SIRNA-directed in vivo silencing of androgen receptor inhibits the growth of castration-resistant prostate carcinomas. PLoS ONE 2007; 10: e1006.
46. Kohli M, Tindall DJ,. Developments in the medical management of prostate cancer. Mayo Clin Proc 2010; 85 (1): 77-86.
47. Sakamoto S, McCann RO, Dhir R, Kyprianou N,. Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 2010; 70 (5): 1885-1895.
48. Wegiel B, Jiborn T, Abrahamson M, Helczynski L, Otterbein L, Persson JL, Bjartell A,. Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways. PLoS ONE 2009; 4 (11): e7953.
49. Bennett N, Hooper JD, Lee CS, Gobe GC,. Critical review androgen receptor and caveolin-1 in prostate cancer. IUBMB Life 2009; 61 (10): 961-970.